Skip to main content
. Author manuscript; available in PMC: 2017 Feb 1.
Published in final edited form as: Cancer Prev Res (Phila). 2015 Dec 28;9(2):172–179. doi: 10.1158/1940-6207.CAPR-15-0186

Figure 3. Validation of the Doylestown algorithm in the NCI EDRN sample set and in an HBV infected sample set from Thomas Jefferson University.

Figure 3

A) AUROC of AFP or the Doylestown algorithm in the NCI EDRN validation set in all patients. B) AUROC of AFP or the Doylestown algorithm in the NCI EDRN validation set in patients with early stage HCC. C) AUROC of AFP versus the Doylestown algorithm in the Thomas Jefferson University validation group. Dotted line is the line of 95% specificity.